A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
Status:
Completed
Trial end date:
2017-07-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group
study designed to evaluate the effects of RO5459072 treatment on disease activity and
symptoms of Sjogren's syndrome in adult participants with moderate to severe primary
Sjogren's syndrome. The total duration of the study for each participant will be
approximately 18 weeks (including screening).